Impact of Hepatitis C Virus Genotype 3 on Liver Disease Progression in a Chinese National Cohort
Hepatitis C virus (HCV) infection remains a significant global health burden, with genotype 3 emerging as a particularly concerning strain due to its association with accelerated liver disease progression and suboptimal response to direct-acting antivirals (DAAs). In China, where HCV genotype 1 is predominant, recent epidemiological shifts have highlighted a rise in genotype 3 prevalence, particularly subtype 3b. This study, conducted through a multicenter cohort across five geographic regions in China, evaluated the clinical characteristics, transmission patterns, treatment outcomes, and disease progression of HCV genotype 3 infection, with a focus on subtype-specific differences.
Study Design and Methodology
The research comprised two phases: a cross-sectional observational study (2011) and a 5-year prospective follow-up (2012–2018). A total of 997 treatment-naïve Han Chinese patients with chronic HCV infection were enrolled, including 91 with genotype 3 (35 subtype 3a, 52 subtype 3b, 4 undefined). The follow-up phase included 512 patients, with 41 carrying genotype 3. HCV genotyping utilized the Versant HCV Genotype 2.0 Assay, while host interleukin 28B (IL28B) and inosine triphosphate pyrophosphatase (ITPA) polymorphisms were analyzed using iPLEX Gold.
Disease progression was defined as: (1) new cirrhosis diagnosis; (2) worsening Child-Turcotte-Pugh (CTP) scores (≥2 points); (3) progression from compensated to decompensated cirrhosis; (4) hepatocellular carcinoma (HCC); (5) liver transplantation; or (6) death. Time-to-event analyses employed Kaplan-Meier estimates and Cox regression to identify risk factors.
Geographical and Subtype Distribution
HCV genotype 3 accounted for 9.1% (91/997) of the cohort, with subtype 3b (57.1%) more prevalent than 3a (38.5%). Regional variations were striking: Southern China had the highest proportion (25.2%, 39/155), particularly in Yunnan Province (65.0%, 26/40), followed by Western (10.5%, 22/209) and Northern (6.1%, 11/181) regions. Genotype 3 was rare in Central China (1.7%, 4/235). These findings align with prior reports linking subtype 3b to intravenous drug use (IVDU) in Southern China and highlight evolving epidemiological trends.
Clinical Characteristics and Host Factors
Patients with genotype 3 were younger (median age: 38 years) than those with genotype 1 (46.9 years). Subtype 3b patients were older than 3a (median 39.5 vs. 35.0 years, P=0.002) and had lower median alanine aminotransferase (ALT) levels (72.0 vs. 97.0 U/L, P=0.012). Notably, diabetes was exclusive to subtype 3b (13.5% vs. 0%, P=0.038), suggesting metabolic interactions unique to this subtype.
Host genetic analysis revealed high prevalence of IL28B CC (rs12979860, 95.6%) and TT (rs8099917, 95.6%) genotypes, consistent with Asian populations. ITPA CC (rs1127354) was more frequent in 3a (74.3%) than 3b (65.4%), though statistically insignificant.
Transmission Risk Factors
IVDU was the predominant risk factor (40.7%), especially in Southern (74%) and Northern (73%) regions. Subtype 3b showed stronger association with IVDU (48.1% vs. 34.3% for 3a), while 3a correlated with blood transfusion (25.7% vs. 9.6%, P=0.045). Regional disparities were evident: dental procedures dominated in the East (40%), while tattoos/piercings and blood transfusions were common in the West (27% each). Over 27% reported multiple exposures, underscoring heterogeneous transmission pathways.
Treatment Outcomes
During follow-up, 58.5% (24/41) of genotype 3 patients received interferon-based therapy (median duration: 47.5 weeks). Subtype 3b achieved higher sustained virologic response at 24 weeks (SVR24) than 3a (100% vs. 66.7%), possibly due to extended treatment duration (49.8 vs. 41.8 weeks). However, these findings predate DAA availability in China, and DAAs’ inferior efficacy against subtype 3b (50% SVR12 in cirrhotics) remains a concern.
Disease Progression
Genotype 3b was associated with accelerated liver disease progression. Over 5 years, 9.8% (4/41) of genotype 3 patients experienced disease progression, all subtype 3b (15.4%, 4/26 vs. 0% for 3a). Kaplan-Meier analysis showed shorter median time from estimated infection to progression for genotype 3b vs. 1 (27.1 vs. 35.6 years). Cox regression identified age ≥40 years (HR=4.94, P<0.001), abnormal aspartate aminotransferase (AST, HR=18.83, P<0.001), and platelet count <100×10³/µL (HR=0.21, P<0.001) as independent predictors. Diabetes, though prevalent in 3b, lacked statistical significance in multivariable analysis.
Discussion
This study provides critical insights into HCV genotype 3’s clinical trajectory in China. Subtype 3b’s rapid progression aligns with global reports of genotype 3’s steatogenic and pro-fibrotic effects. The younger age and metabolic profile (diabetes) of 3b patients suggest synergistic mechanisms driving hepatic injury. Regional transmission patterns reflect IVDU’s role in Southern China and iatrogenic exposures elsewhere, necessitating tailored prevention strategies.
Interferon-based therapies achieved high SVR24 for 3b, but DAA-era data are urgently needed. Prior studies report <50% SVR12 in cirrhotic 3b patients treated with sofosbuvir/velpatasvir, compounded by baseline resistance mutations. Ribavirin’s hemolytic risk in ITPA CC carriers (68.1% of cohort) further complicates therapy, emphasizing the need for ribavirin-free regimens.
Limitations and Future Directions
The study’s follow-up phase was limited by genotype 3’s low prevalence and lack of DAA exposure. Subtype 3a’s smaller sample size and attrition at 25 years may underestimate its progression risk. Future studies in high-prevalence regions should delineate subtype-specific mechanisms and optimize DAA strategies.
Conclusion
HCV genotype 3, particularly subtype 3b, represents a growing public health challenge in China due to aggressive disease progression and treatment complexities. Enhanced screening, targeted interventions for high-risk populations, and development of subtype-specific therapies are imperative to mitigate HCV-related morbidity.
doi.org/10.1097/CM9.0000000000000629
Was this helpful?
0 / 0